medigraphic.com
ISSN 1561-2937 (Print)

2020, Number 4

<< Back Next >>

Rev Cubana Cardiol Cir Cardiovasc 2020; 26 (4)

Clinical evolution of infective endocarditis in patients treated with Meropenem

González GM, Ramos EC, Gutiérrez LA, Tadeo NJA

Language: Spanish
References: 24
Page: 2-9
PDF size: 182.84 Kb.


ABSTRACT

Introduction: Infectious endocarditis (IE) is a serious and potentially fatal disease. In our country there are few studies on the use of Meropenem in these patients. Objective: To characterize the clinical-epidemiological variables in patients diagnosed with infectious En-docarditis treated with Meropenem. Methodological design: A descriptive, cross-sectional observational study was conducted with 41 patients diagnosed with IE, treated with Meropenem, at the ¨Hermanos Ameijeiras¨ Clinical-Surgical Hospital; in the period between January 2006 and January 2018. Descriptive statistics were used, the mean, standard deviation and percentages were calculated. Results: The mean age was 56.6 ± 17.1 years, predominantly the age group of 50 to 69 years (43.9%), infective endocarditis in the left native valve (43.9) and Staphylococcus as a germ more frequent (43.9%). It was found as predisposing factors more linked to IE, acquired valvular disease (34.1%) and mechanical valve prostheses (31.7%); the oral route being the most frequent entrance door (36.6%). The complication rate was high (78%), with the majority of patients requiring surgical treatment; however, the number of deaths (26.8%) was lower, during clinical evolution. Conclusions: Predisposing factors more related to IE, male sex, age between 50 and 69 years, acquired valvular disease and mechanical valve prostheses were found; the oral route being the most frequent entrance door. The complication rate was high due to the characteristics of the sample studied. The majority of patients required surgical intervention. Treatment with meropenem was beneficial in the management of these serious patients, with fewer patients who died during the clinical course.


REFERENCES

  1. Flores P, González N, Betancourt P, Berho J, Astudillo C, García C, et al. Endocarditis In-fecciosa: caracterización clínica de la enfermedad. Revisión de casos de los últimos 5 años. Rev Chil Cardiol 2017; 36: 34-40.

  2. Selton-Suty C, Célard M, Le Moing V, Doco-Lecompte T, Chirouze C, Lung B, et al. Preeminence of Staphylococcus aureus in infective endocarditis: a 1-year population-based survey. Clin Infect Dis 2012; 54:1230–9.

  3. Fernandez-Gerlinger MP, Mainardi JL. Endocarditis infecciosa: del diagnóstico al tratamiento. EMC - Tratado de medicina 2016; 20 (4):1-7.

  4. Mora GA, González EA. Endocarditis Infecciosa. Revista Médica de Costa Rica y Centroamérica LXXI. 2014; (609): 9 – 13.

  5. Castillo JC, Anguita MP, Ruiz M, Peña L, Santisteban M, Puentes M, et. al. Cam-bios epidemiológicos de la endocarditis infecciosa sobre válvula nativa. Rev Esp Cardiol. 2011; 64(7): 594-98.

  6. Castillo FJ, Anguita M, Castillo JC, Ruiz M, Mesa D, Suárez JL. Cambios en el perfil clínico, epidemiológico y pronóstico de la endocarditis infecciosa nativa izquierda sin lesión cardiaca predisponente. Rev Esp Cardiol. 2015;68(5):445– 48.

  7. Habib G, Salaun E, Hubert S. Infective Endocarditis: A Deadly Disease if Diag-nosed Too Late. Journal of the American Society of Echocardiography. 2016; 29 (4): 323-24.

  8. Baddour LM, Freeman WK, Suri RM, Wilson WR. Infecciones cardiovasculares. En: Mann DL, Zipes DP, Libby P, Bonow RO. Braunwald. Tratado de cardiología. 10ma ed. España, Elsevier. 2016; 64: 1524-50.

  9. Mestres CA, Paré JC, Miró JM, Pericás JM, Cervera C, García de la María C, et al. Organización y funcionamiento de un grupo multidisciplinario de diagnóstico y tratamiento de la endocarditis infecciosa: perspectiva de 30 años (1985–2014). Rev Esp Cardiol. 2015;68(5):363–368.

  10. Habib G, Lancellotti P, Antunes MJ, Bongiorni MG, Casalta JP, Del Zotti F, et al. Guía ESC 2015 sobre el tratamiento de la endocarditis infecciosa. Rev Esp Cardiol. 2016; 69(1): 69. e1-e49.

  11. Ordóñez KM, Hernández OA, Cortés JA, López, MJ, Alfonso G, Junca, A. Endo-carditis infecciosa izquierda por Pseudomonas aeruginosa tratada médicamente. Biomédica 2010; 30:164-9.

  12. Yoshino Y, OMichel P, Gaete P. Endocarditis infecciosa por Aerococcus species: Caso clínico y revisión de la literatura. Revista ANACEM 2011; 5(1):49-51.

  13. Pérez V, García J, Domínguez FJ, Gómez IM. Endocarditis infecciosa por Ochro-bactrum anthropi en paciente inmunocompetente. Enferm Infecc Microbiol Clin 2005;23(2):110-2.

  14. Fernández-Hidalgo N, Almirante B. La endocarditis infecciosa en el siglo XXI: cambios epidemiológicos, terapéuticos y pronósticos. Enferm Infecc Microbiol Clin 2012; 30(7):394–406.

  15. Leyva Quert AY, Ruiz Camejo T, González Corrig M, Méndez Peralta T, Ramos Emperador C, Almeida Gómez J. Perfil clínico, epidemiológico y microbiológico de la endo-carditis infecciosa en el Hospital “Hermanos Ameijeiras”, 2005-2008. Revista Cubana de Medicina 2009; 48(3):1-14.

  16. Moreillon P, Que YA. Infective endocarditis. Lancet. 2004; 363: 139-49.

  17. Heiro M, Helenius H, Mäkilä S, Hohenthal U, Savunen T, Engblom E, et al. Infec-tive endocarditis in a Finnish teaching hospital: a study on 326 episodes treated during 1980-2004. Heart. 2006;92;1457-62.

  18. Carrasco F, Anguita M, Castillo F, Castillo JC, Ruiz M, Romo E. Diferencias en la morbimortalidad y tasa de cirugía en relación a la forma clínica de endocarditis infecciosa. Rev Esp Cardiol. 2014;67 Supl 1:892.

  19. Cremona AR, Ramírez Borga SJ, Losinno JF, Cartasegna LR, Escudero EM, Fer-nández JL, et al. Variables predictoras de embolias en endocarditis Infecciosa. Medicina (Buenos Aires) 2007; 67:39-43.

  20. Chu VH, Cabell CH, Benjamin DK, Kuniholm EF, Fowler VG, Engemann J, et.al. Early Predictors of In-Hospital Death in Infective Endocarditis. Circulation. 2004; 109 (14): 1745-49.

  21. Rosso F, Cedano JA, Franco-Molina MA, Borrero-González AF, García-Robledo JA. Comparación de las características y curso clínico de la endocarditis infecciosa por Sta-phylococcus aureus meticilino sensible versus meticilino resistente. Rev Colomb Cardiol. 2018; 2018;25(5):314-320.

  22. Serra Valdés MA. Endocarditis infecciosa estudio anatomoclínico de fallecidos 2001-2006. Revista Habanera de Ciencias Médicas 2012:11(2)198-209.

  23. Martínez M, Arnaiz AM, Muñoz P, Bouza E. Cirugía de la endocarditis infecciosa: factores determinantes del pronóstico intrahospitalario. Rev Esp Cardiol. 2012;65 Supl 3:156.

  24. Kang DH, Kim YJ, Kim SH, Sun BJ, Kim DH, et al. Early surgery versus conven-tional treatment for infective endocarditis. N Engl J Med.2012;366:2466–73.




2020     |     www.medigraphic.com